Manila Times Business
CERo Therapeutics Announces Clinical Update from CERTAIN-T Phase 1 CER-1236 Trial, Including Patient Undergoing Allogeneic Stem Cell Transplant Following Treatment
Fifth patient treated with CER-1236 underwent stem cell transplant following lack of response to prior therapies; Company initiates third planned cohort in ongoing Phase 1 study in hematologic malignancies SOUTH SAN FRANCISCO, Calif, June 15, 2026 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (OTCQB: CERO) ("CERo” or the "Company”), an innovative cellular immunotherapy company advancing engineered T cell therapeutics designed to engage phagocytic mechanisms, today announced a clinical upd
This is an excerpt. Read the full article at the original source:
Source: manilatimes.net
Read Full Article on manilatimes.net →More from Manila Times Business
Twenty-six years later: Finally seeing the first sunrise at Pusan Point
Just now
BSB Junrose strengthens portfolio for hybrid, EV, and conventional vehicles
Just now
FAW trucks launches 'Wheels of Hope' outreach for Rizal school
Just now
100x Leverage, No KYC, $50 Welcome Bonus, and Double Deposit Bonus - Trade Crypto Futures on BexBack
Just now